The plant hormone jasmonate plays crucial roles in regulating plant responses to herbivorous insects and microbial pathogens and is an important regulator of plant growth and development [1][2][3][4][5][6][7] . Key mediators of jasmonate signalling include MYC transcription factors, which are repressed by jasmonate ZIM-domain (JAZ) transcriptional repressors in the resting state. In the presence of active jasmonate, JAZ proteins function as jasmonate co-receptors by forming a hormone-dependent complex with COI1, the F-box subunit of an SCF-type ubiquitin E3 ligase [8] [9] [10] [11] . The hormone-dependent formation of the COI1-JAZ co-receptor complex leads to ubiquitination and proteasome-dependent degradation of JAZ repressors and release of MYC proteins from transcriptional repression 3,10,12 . The mechanism by which JAZ proteins repress MYC transcription factors and how JAZ proteins switch between the repressor function in the absence of hormone and the co-receptor function in the presence of hormone remain enigmatic. Here we show that Arabidopsis MYC3 undergoes pronounced conformational changes when bound to the conserved Jas motif of the JAZ9 repressor. The Jas motif, previously shown to bind to hormone as a partly unwound helix, forms a complete a-helix that displaces the amino (N)-terminal helix of MYC3 and becomes an integral part of the MYC N-terminal fold. In this position, the Jas helix competitively inhibits MYC3 interaction with the MED25 subunit of the transcriptional Mediator complex. Our structural and functional studies elucidate a dynamic molecular switch mechanism that governs the repression and activation of a major plant hormone pathway.
The plant hormone jasmonate plays crucial roles in regulating plant responses to herbivorous insects and microbial pathogens and is an important regulator of plant growth and development [1] [2] [3] [4] [5] [6] [7] . Key mediators of jasmonate signalling include MYC transcription factors, which are repressed by jasmonate ZIM-domain (JAZ) transcriptional repressors in the resting state. In the presence of active jasmonate, JAZ proteins function as jasmonate co-receptors by forming a hormone-dependent complex with COI1, the F-box subunit of an SCF-type ubiquitin E3 ligase [8] [9] [10] [11] . The hormone-dependent formation of the COI1-JAZ co-receptor complex leads to ubiquitination and proteasome-dependent degradation of JAZ repressors and release of MYC proteins from transcriptional repression 3,10,12 . The mechanism by which JAZ proteins repress MYC transcription factors and how JAZ proteins switch between the repressor function in the absence of hormone and the co-receptor function in the presence of hormone remain enigmatic. Here we show that Arabidopsis MYC3 undergoes pronounced conformational changes when bound to the conserved Jas motif of the JAZ9 repressor. The Jas motif, previously shown to bind to hormone as a partly unwound helix, forms a complete a-helix that displaces the amino (N)-terminal helix of MYC3 and becomes an integral part of the MYC N-terminal fold. In this position, the Jas helix competitively inhibits MYC3 interaction with the MED25 subunit of the transcriptional Mediator complex. Our structural and functional studies elucidate a dynamic molecular switch mechanism that governs the repression and activation of a major plant hormone pathway.
To understand the structural basis of the interactions between MYC transcription factors and JAZ repressors, we first used yeast twohybrid assays to determine the JAZ-binding regions within MYC2, MYC3 and MYC4. A conserved region of ,200 amino acids (amino acids 55-259, 44-234 and 55-253 in MYC2, MYC3 and MYC4, respectively) within the N termini of all three proteins that encompasses the previously defined JAZ-interacting domain (JID) 13, 14 and the transcription activation domain (TAD) 13, 15 was sufficient to interact with JAZ9 (Extended Data Figs 1a and 2a) . Similarly, we identified a region of 17 amino acids within the Jas motif of JAZ9 (polyA-Jas) that is required and sufficient to interact with MYC3 (Extended Data Fig. 1b ). Interestingly, this Jas motif shares the same segment of JAZ proteins that interacts with COI1 (ref. 16 ), but is four amino acids shorter at the N terminus (Extended Data Fig. 1c ). We confirmed these results using AlphaScreen luminescence proximity assays with His6-tagged MYC proteins and biotinylated JAZ8, JAZ9 and JAZ12 peptides (Extended Data  Figs 1d and 2b) .
On the basis of our mapping results, we generated 15 MYC2/3/4 N-terminal truncated proteins of various lengths (Extended Data Figs 1d and 2b). MYC3(44-238) and MYC3(5-242) yielded highquality crystals that diffracted X-rays to 2.2 Å and 2.1 Å resolution, respectively (Extended Data Table 1 ). We solved the structure of selenomethionine-modified MYC3(44-238) by selenium singlewavelength anomalous diffraction (Se-SAD) and the structure of MYC3(5-242) by molecular replacement using the structure of MYC3(44-238) as search model (Fig. 1a, b and Extended Data Fig. 3 ). The proteins formed a helix-sheet-helix sandwich fold, in which eight a-helices are wrapped around a central five-stranded antiparallel b-sheet ( Fig. 1a) . Remarkably, while a hallmark of acidic TAD is that they are unstructured when not bound to a target in the transcriptional machinery [17] [18] [19] , the MYC3 TAD is well resolved and forms a loop-helix-loop-helix motif that packs against the JID with the N-terminal TAD helix and against b-strands 3-5 with the carboxy (C)-terminal TAD helix (Fig. 1a, b and Extended Data Fig. 3 ). To our knowledge, this is the first example in which a non-complexed acidic TAD has a well-resolved structure. The JID consists of the top (b2) strand of the b-sheet, the long a3-helix and two unresolved linkers ( Fig. 1a, b and Extended Data Fig. 3a ). In MYC3(5-242), the JID forms together with the a4-helix of the TAD groove. The N-terminal MYC helix (a1) is connected by a sharp ,90u kink to a loop that adopts a partial, stretched-out helical conformation (a19, amino acids 6-16) that occupies the groove formed by the JID and TAD to cap the central b-sheet ( Fig. 1a and Extended Data Fig. 3a ). In N-terminally truncated MYC3 (MYC3(44-238), which lacks a19 1 a1), the JID rearranges to adopt a position similar to that of a19 in MYC3(5-242) to substitute for a19 to cap the b-sheet in the fold (Fig. 1b ). We performed hydrogen deuterium exchange (HDX) experiments to detect the surface accessibility and structural dynamics of MYC3(5-242) in solution (Extended Data Fig. 4 ). While the central b-sheet has a very stable structure and is well protected from deuterium exchange, the a1/a19 helix region has a very high deuterium exchange rate, suggesting that it has a very dynamic structure and forms only transiently in solution. This is consistent with the high B-factor values of the a1/a19 helix in the MYC3(5-242) crystal structure (Extended Data Fig. 5 ). While peptides corresponding to the JID helix were not resolved in HDX experiments, the JID helix also has a high B-factor (Extended Data Fig. 5 ), indicating that its position is dynamic as well. The MYC3(5-242) and MYC3(44-238) apo crystal structures therefore probably represent structure snapshots of two or more alternative MYC3 conformations in solutions.
To crystallize a complex between MYC and the Jas motif, we synthesized a set of nine JAZ8, JAZ9 and JAZ12 Jas peptides of different lengths and complexed them with the above-mentioned set of the MYC N-terminal proteins. After extensive trials, we succeeded in obtaining crystals for MYC3(44-238) in complex with a 22-amino-acid Jas peptide (S218-M239) from JAZ9 (Jas22 JAZ9 ). However, no crystals for MYC3(5-242)-Jas peptide complexes could be obtained, suggesting that Jas complexes with a19/a1 helixcontaining MYC3 are less stable and/or conformationally more dynamic. To test this hypothesis, we generated a covalent fusion between MYC3(5-242) and Jas22 JAZ9 separated by a 12-amino-acid flexible linker to increase the stability of the MYC3(5-242) and Jas22 JAZ9 complex and reduce conformational flexibility. This fusion protein formed high-quality crystals and allowed us to solve the structure of the MYC3(5-242)-Jas22 JAZ9 complex (Fig. 1c ) at a resolution of 2.4 Å (Extended Data Table 1 ). The most striking aspect of the MYC3(5-242)-Jas22 JAZ9 complex is that the Jas peptide formed a single, continuous helix that displaced the dynamic a19/a1 helix in apo MYC3(5-242) (Supplementary Video 1). Correspondingly, the JID helix rearranged its conformation and the displaced a19/a1 helix became almost completely disordered, suggesting the increase in disorder as the likely reason for the recalcitrance of this complex to crystallize. The Jas helix adopted a position in the groove that is almost superimposable with that of a19 ( Fig. 1e ). In this position the Jas helix is nestled between the a4-helix of the TAD and the strand and helix of the JID to make extensive interactions with both the JID and the TAD and to become an integral part of the structural fold. In addition, we also determined the structure of MYC3(44-238), lacking the a19/a1 helix, in complex with Jas22 JAZ9 peptide at a resolution of 1.95 Å (Extended Data Table 1 ). In this structure, the Jas peptide also adopted a helical conformation and binds to the JID/TAD groove in the same way as seen in the MYC3(5-242)-Jas22 JAZ9 fusion complex ( Fig. 1d , f). Both a19/a1 and the JID helix have long, unresolved linkers that appear to provide flexibility for their displacements/rearrangements by the Jas helix. Together, our analyses of the MYC3 apo and MYC3-JAZ complex structures indicate that occupancy of the groove (either by a19 or the JID helix in apo MYC3, or by the Jas helix in the MYC-JAZ complex) is critical for formation of the overall MYC N-terminal fold.
In the JAZ9-MYC3 complex, the JAZ peptide forms five main interaction networks with the TAD-JID surface ( Fig. 2 and Extended Data Table 2 ): (1) R234 of JAZ9 forms salt bridges and hydrogen bonds with three glutamate residues (E142, E143 and E148) of the TAD; (2) R229 and S226 form charge and hydrogen bond interactions with JID D94 and W92; (3) L227 and L231 form a core hydrophobic network with TAD L152 and JID I122 and L125; (4) F230 interacts with JID Y97 and TAD F151 in an aromatic ring network; and (5) R223 and L227 have both hydrogen bond and/or hydrophobic interactions with TAD M155. In contrast, the first five amino acids (SVPQA) of the Jas motif that are critical for the co-receptor function of JAZ proteins (that is, hormone-dependent binding to COI1 (ref. 16)) made no critical interactions with MYC3, consistent with our yeast two-hybrid and AlphaScreen data (Extended Data Figs 1b, d and 2b). Consistent with the structural data, mutational analysis showed that key interface residues of Jas, JID and TAD have important roles in MYC-JAZ interactions (Fig. 3a, b and Extended Data Fig. 6 ). In addition, the structure also provides an explanation for the partial in vivo relief of MYC3 repression by the MYC3 D94N mutation observed previously 20 , as MYC3 D94N lost interaction with a subset of JAZs, including JAZ3, JAZ4 and JAZ9 (Extended Data Fig. 6 ).
Next, we transfected the MYC-responsive pJAZ2::GUS reporter 21 together with wild-type and mutant MYC3 expression plasmids into Arabidopsis protoplasts. As shown in Fig. 3c , mutant MYC3 proteins that were defective in interaction with multiple JAZ proteins (Extended Data Fig. 6 ) were partly relieved in repression (that is, increased reporter gene activity). Moreover, the extent at which mutations compromised MYC3 interactions with JAZ proteins correlated with the increase in reporter gene activity and the magnitude of changes in reporter gene activity could be further accentuated by expressing MYC3 mutant proteins from the strong cauliflower mosaic virus 35S promoter in coi1-30 mutant protoplasts, in which all JAZ repressors are presumably stabilized ( Fig. 3d ). Together, these data validate the MYC3-JAZ9 complex structure and provide strong evidence that amino-acid interactions identified in the MYC3-JAZ9 complex structure are important for MYC3 repression in planta.
The Jas motif is required for its repressor function through interaction with MYC but also for its co-receptor function through interaction with COI1 (ref. 22) . While the Jas JAZ9 peptide in the MYC3 complex formed a continuous helix ( Fig. 1c, d ), representing the rest state of JAZ, the Jas JAZ1 peptide in the previously determined COI1-jasmonate-Ile-Jas coreceptor structure (Protein Data Bank accession number 3OGL) adopted a bipartite conformation with an N-terminal part stretched to form a distinct loop region followed by a shorter C-terminal helix 16 , as illustrated by the structural alignment in Fig. 4a, b and Supplementary Video 2. In addition to the Jas JAZ9 -MYC3 complex, we solved the structure of the Jas JAZ1 -MYC3 complex. As shown in the structure alignment in Extended Data Fig. 7 , the Jas helices of JAZ9 and JAZ1 overlap very well, confirming that the Jas conformational change between MYCbound (resting stage) and COI1-bound (hormone-activated stage) is probably common in MYC interaction with different JAZ transcriptional repressors.
In the Jas JAZ1 -COI1 complex, the loop region of the Jas JAZ1 helix is formed by the five moderately conserved N-terminal amino acids of the Jas motif (Extended Data Fig. 1c ) that directly interact with the jasmonate-Ile hormone ( Fig. 4a, b ) and is required for Jas-jasmonate-Ile-COI1 co-receptor complex formation 16 . When we mutated the corresponding N-terminal amino acids of JAZ9 to alanine (JAZ9-4A and JAZ9-AA; Fig. 4c ), JAZ9 lost interaction with COI1 in yeast two-hybrid assays, but not with MYC3 ( Fig. 4d ), consistent with the MYC3 complex structure. Mutations in the middle of the Jas motif (S226A-R234A) affected binding to both MYC3 and COI1, albeit to different degrees. In addition, residues that are C-terminal to the Jas motif enhance JAZ9 interaction with COI1 in yeast two-hybrid assays, but are not critical for its interaction with MYC3 ( Fig. 4e, f) , which is consistent with a previous study of JAZ2, JAZ3 and JAZ10 interactions with COI1 and MYC2 (ref. 23 ). Together, these results indicate that COI1 and MYC3 potentially compete for binding to the central part of the Jas motif, but that COI1 makes additional critical interactions with JAZ9 outside the MYC3-interacting region, including the previously unrecognized hormone-dependent unwinding of the N-terminal helix of the Jas motif (Supplementary Video 2). These additional interactions may allow COI1 to drive JAZ ubiquitination and dissociation of the extensive JAZ-MYC interaction upon jasmonate-Ile stimulation. MED25 is a subunit of the Mediator complex that recruits RNA polymerase II to the promoters of jasmonate-responsive genes 24 and is required for various jasmonate responses 13, 15, 25 , including Arabidopsis susceptibility to Pseudomonas syringae bacterial infection (Extended Data Fig. 7c ) and jasmonate-induced inhibition of Arabidopsis root growth (Extended Data Fig. 7d ). We found that MYC3(44-238) also directly binds MED25 and that a fragment (amino acids 540-680) encompassing the MED25 activator interaction domain (ACID) is sufficient to bind to MYC3 (Fig. 5a) , analogous to what has previously been reported for MYC2 (ref. 13 ). Since the MYC3 TAD makes critical interactions with JAZ repressors and is required for MYC3-JAZ9 complex formation (Figs 2 and 3b and Extended Data Fig. 6 ), we explored the intriguing possibility that MYC3 binding of JAZ9 and MED25 is mutually exclusive. To test this prediction in a defined system, we performed AlphaScreen interaction assays between MED25(407-680) and both MYC3(44-238) and MYC3(5-242) in the presence of increasing amounts of untagged Jas22 JAZ9 peptide. As shown in Fig. 5b , the JAZ peptide competitively inhibited the MYC-MED25 interaction with an IC 50 of ,420 nM (MYC3(44-238)) and ,490 nM (MYC3(5-242)). We further tested competition in planta by transiently expressing combinations of tagged MED25, JAZ9 and MYC3 in Nicotiana tabacum leaves. As shown in Fig. 5c , co-immunoprecipitation of MED25 with MYC3 was strongly reduced upon co-expression of JAZ9. Together, these results demonstrate that the Jas motif of JAZ proteins and the ACID domain of MED25 probably bind to a shared MYC3 surface, and that JAZ repressors can compete with MYC3 for interaction with MED25 (and possibly other co-activators) in vitro and in planta.
In the past decade, despite the identification of analogous hormone perception and transcriptional gene regulation that underpins several hormone signal transduction pathways in plants 26 , no crystal structures of the transcriptional-repressor-transcription-factor complexes 
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have been solved. The crystal structure of the MYC-JAZ complex reported here therefore provides the first structural insight into the mechanism of transcriptional repression in plant hormone signalling. Our structural, biochemical and in planta analyses suggest that JAZ repressors use a novel dual repression mechanism, which involves not only epigenetic modifications of the target gene chromatin structure through TOPLESS co-repressors, as demonstrated previously 27 , but also direct inhibition of MYC binding to MED25 (and possibly other co-activators), as an integral part of a mechanism of preventing transcriptional activation of jasmonate response genes (Extended Data Fig. 8 ). In addition, we have discovered distinct JAZ conformations in the MYC-JAZ resting complex versus the JAZ-COI1 hormone-activated complex 16 , providing the first structural insight into the switch mechanism between transcriptional repression and hormone-dependent transcriptional activation in a major plant hormone signalling pathway.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Supplementary Fig. 1 , and associated original data in Supplementary Table 1 . c, Interference of the MYC3-MED25 interaction by JAZ9 in planta. Flag-MED25 (1), haemagglutinin epitope tag (HA)-JAZ9 (1) and YFP-MYC3 (1), and respective vector controls carrying Flag, HA or YFP tags (2) under control of the cauliflower mosaic virus 35S promoter were transiently expressed in N. tabacum leaves. Protein extracts were immunoprecipitated (IP) with an anti-YFP antibody and analysed by western blot (WB) with HA-, Flag-, or YFP-specific antibodies. The experiment was repeated three times with similar results. The original blots from which the images were cropped are shown in Supplementary Fig. 2 . 
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METHODS
Protein preparation. Wild-type MYC3(44-238) was expressed as a fusion protein with a cleavable N-terminal His6Sumo tag from a modified pSUMO (LifeSensors) expression vector. BL21 (DE3) cells transformed with the expression plasmid were grown in Luria-Bertani broth at 16 uC to an absorbance (A 600 nm ) of ,1.0 and induced with 0.1 mM IPTG for 16 h. Cells were harvested, resuspended in 100 ml extract buffer (20 mM Tris, pH 8.0, 200 mM NaCl, and 10% glycerol) per 6 l of cells and passed three times through a French press with pressure set at 1,000 Pa. The lysate was centrifuged at 40,900g in a Sorvall SS34 rotor for 30 min, and the supernatant was loaded on a 50 ml nickel HP column. The column was washed with 600 ml of 10% buffer B (20 mM Tris, pH 8.0, 200 mM NaCl, 500 mM imidazole and 10% glycerol) and eluted with 200 ml of 50% buffer B, followed by 100 ml of 100% buffer B. The eluted His6Sumo-MYC3(44-238) was dialysed against extract buffer and cleaved overnight with SUMO protease at a protease:protein ratio of 1:1,000 at 4 uC. The cleaved His6Sumo tag was removed by passing through a 5 ml nickel HP column, and the protein was further purified by chromatography through a HiLoad 26/60 Superdex 200 gel filtration column in 25 mM Tris, pH 8.0, 200 mM ammonium acetate, 1 mM dithiothreitol and 1 mM EDTA.
To prepare the protein-ligand complex, we mixed Jas22 JAZ1 , Jas22 JAZ8 , Jas22 JAZ9 or Jas22 JAZ12 peptides with purified MYC3(44-238) proteins at a 1.5:1 molar ratio. The expression and purification of MYC3(5-242) followed the same method as for MYC3(44-238) described above. To prepare the protein-ligand complex, we mixed Jas22 JAZ1 , Jas22 JAZ8 , Jas22 JAZ9 or Jas22 JAZ12 peptides with purified MYC3(5-242) proteins at a 1.5:1 molar ratio. To prepare MYC3(44-238) selenomethionyl (Se-Met) protein for phase determination, we followed the same methods as described previously 28 . Purification of Se-Met MYC3(44-238) proteins followed the same protocol as for MYC3(44-238) native protein except that the procedure was performed more quickly to avoid protein oxidization. The MYC3(5-242)-Jas22 JAZ9 complex was constructed as a fusion protein with His6Sumo-MYC3(5-242) at the N terminus and Jas22 JAZ9 at the C terminus, separated by a flexible GSAGSAGSAGSA (43GSA) linker (His6Sumo-MYC3(5-242)-4 3 GSA-Jas22 JAZ9 ). The expression and purification of the fusion protein followed the same methods as for MYC3(44-238).
Small-scale purification of His6Sumo-tagged MYC2/3/4 protein fragments (including JID and TAD domain) for binding studies with Jas peptides followed the same methods as for MYC3(44-238), except that the His6Sumo tag was not removed. Small-scale purification of His6Sumo-tagged MED25 protein fragments (including the ACID domain) for binding studies with biotinylated MYC3(44-238) followed the same methods as for MYC3(44-238), except that the His6Sumo tag was not removed. To express and purify biotinylated MYC3(44-238) and MYC3(5-242) protein for binding studies (Fig. 5a ) and JAZ Jas competition assays (Fig. 5b) , we followed the methods described previously 29 . Crystallization. The apo-MYC3(5-242) crystals were grown at 20 uC in sitting drops containing 0.2 ml of purified MYC3(5-242) protein at a concentration of 10 mg ml 21 and 0.2 ml of well solution containing 0.2 M magnesium chloride, 0.1 M Tris, pH 8.5, 30% (w/v) polyethylene glycol 4000 for 3 days. The Se-Met MYC3(44-238) crystals were grown at 20 uC in sitting drops containing 0.2 ml of the purified protein at a concentration of 15 mg ml 21 and 0.2 ml of well solution containing 0.2 M sodium chloride, 0.1 M Bis-Tris, pH 5.5 and 25% (w/v) polyethylene glycol 3,350. Crystals of about 100 mm in length appeared in 3 days. The MYC3(44-238)-Jas22 JAZ9 complex crystals were grown at 20 uC in sitting drops containing 0.2 ml of the purified complex proteins at a concentration of 15 mg ml 21 and 0.2 ml of well solution containing 0.2 M magnesium chloride, 0.1 M Tris, pH 8.5 and 30% (w/v) polyethylene glycol 4000 for 3 days. The MYC3(44-238)-Jas22 JAZ1 complex crystals were grown at 20 uC in sitting drops containing 0.2 ml of the purified complex proteins at a concentration of 15 mg ml 21 and 0.2 ml of well solution containing 3.5 M sodium formate. Crystals of about 80 mm in length appeared in 2 days. The MYC3(5-242)-Jas22 JAZ9 fusion protein crystals were grown at 20 uC in sitting drops containing 0.2 ml of the purified fusion proteins at a concentration of 15 mg ml 21 and 0.2 ml of well solution containing 0.2 M magnesium nitrate, 20% (w/v) polyethylene glycol 3350. Crystals of about 100 mm in length appeared in 3 days. All crystals were serially transferred to the well solution with 20% (v/v) ethylene glycol before flash freezing in liquid nitrogen. Data collection and structure determination. Data collections were performed at sector 21-ID (LS-CAT) beam lines of the Advanced Photon Source synchrotron using single native MYC3(5-242) crystals, MYC3(44-238)-Jas22 JAZ9 complex crystals and Se-Met-substituted MYC3(44-238) crystals at different wavelengths. All diffraction data were processed using XDS 30 , and merged using Aimless of the CCP4 suite 31 . Initial phasing was tried by using the SAD method based on anomalous diffraction of sulfur atoms as previously described 32 . S-SAD phasing using a combined data set of 11 native MYC3(5-242) crystals collected at 1.77 Å was not successful, probably because of the non-isomorphism of the individual crystals. To solve the phase problem, the Se-Met-substituted MYC3(44-238) crystals were prepared and a single data set was collected at a peak wavelength of 0.9787 Å (Extended Data Table 1 ). Se-SAD phasing was performed by using the Phenix Autosol program. Five out of six selenium atoms were found with a figure of merit (FOM) value of 0.41. The Phenix autobuild program generated an initial model of 286 residues with a value of R work /R free of 0.35/0.40. Further model improvements were performed using Coot 33 and refined using the Refmac program in CCP4 (ref. 34 ) to a final model with an R factor of 0.21 and an R free factor of 0.26. The MYC3(5-242) apo structure, MYC3(5-242)-Jas22 JAZ9 , MYC3(44-238)-Jas22 JAZ9 and MYC3(44-238)-Jas22 JAZ1 complex structures were solved by using the molecular replacement program Phaser 35 with the Se-Met MYC3(44-238) structure as a search model. The model for the a19/a1 helices for the MYC3(5-242) structure, for the Jas22 JAZ9 peptide for the MYC3(44-238)-Jas22 JAZ9 and MYC3(5-242)-Jas22 JAZ9 complex structures and for the Jas22 JAZ1 peptide for the MYC3(44-238)-Jas22 JAZ1 complex structure were built on the basis of the electron density maps using Coot. AlphaScreen luminescence proximity assays. In vitro interactions between MYC3 and Jas peptides or MED25 fragments were assessed by luminescence proximity AlphaScreen (PerkinElmer) technology as described previously 29, 36, 37 . Reactions contained 50 nM His6Sumo-MYC3 protein bound to nickel-acceptor beads and 50 nM synthesized biotinylated Jas peptides bound to streptavidin donor beads (Extended Data Fig. 1d and 2b) or 50 nM His6Sumo-MED25-ACID protein bound to nickel-acceptor beads and 50 nM biotin-MYC3(44-238) bound to streptavidin donor beads (Fig. 5a) . The results were based on an average of three experiments with standard errors typically less than 10% of the measurement.
For the competition assay ( Fig. 5b) , non-biotinylated Jas22 JAZ9 peptide was added into the reaction at concentrations of 0, 5, 10, 100, 300, 1,000, 3,000, 10,000, 30,000 and 100,000 nM. The results were based on an average of three experiments with standard errors typically less than 10% of the measurement. Mutagenesis. Site-directed mutagenesis was performed using the QuickChange Method (Agilent). Mutations for all plasmid constructs were confirmed by sequencing. Yeast two-hybrid assays. Most of the constructs for yeast two-hybrid assays used in this study were described previously 22, 38, 39 . The coding sequences of full-length MYC2, MYC3 and MYC4, and MYC N-terminal and C-terminal fragments were PCR-amplified and cloned into pGilda (Clontech). PCR-based deletions were conducted following the manufacturer's protocol (Stratagene). Detailed protocols for yeast two-hybrid assays were described previously 38 . Plant materials and growth conditions. Arabidopsis plants used in this study were previously described 39 or were ordered from the Arabidopsis Biological Resource Center (www.arabidopsis.org). Arabidopsis seeds were stratified for 3 days at 4 uC before planting. The soil-grown plants were placed in a controlled growth chamber at 23 uC with a 12-h-day (80 mmol s 21 m 22 cool-white fluorescent light)/12-h-night cycle. Transient expression in tobacco leaves and Arabidopsis protoplasts. For transient expression in tobacco leaves, coding sequences of JAZ9, MED25 and MYC3 were cloned into pJYP003, pJYP011 and pJYP018 (J.Y. and S.Y.H., unpublished observations), respectively, to create p35S:33HA-JAZ9, p35S:33Flag-MED25 and p35S:YFP-MYC3 fusion constructs, which were transfected as previously described 39 . Protein extracts were immunoprecipitated with an anti-YFP antibody and analysed by western blot with anti-HA, -Flag or -YFP antibodies as previously described 39 . For transient expression in Arabidopsis mesophyll protoplasts, MYC3 (no stop codon) with or without its promoter (the 2-kb sequence upstream of the start codon) was PCR-amplified and cloned into pENTR-D/TOPO vector (Invitrogen) to create entry clones. Then, the MYC3 or pMYC3:MYC3 inserts were introduced into pSAT4A-DEST-Venus or pBR-DEST-Venus (J.Y. and S.Y.H., unpublished observations) to create the p35S:MYC3-YFP or pMYC3-MYC3-YFP constructs. The JAZ2 promoter (the 2-kb sequence upstream of its start codon) was cloned into pBR-Gus (J.Y. and S.Y.H., unpublished observations) to create pJAZ2:GUS reporter constructs. The transient expression assays using pBS-35S-Luc as transfection control followed a published protocol 40 . A 35S::LUC reporter construct was co-transfected as a control. GUS activities were normalized to the luciferase activity. Root growth inhibition assay. Arabidopsis wild-type (Col-0) and med25 (pft1-2; SALK_129555) 25 seedlings were used for the root growth inhibition assay. Seeds were surface-sterilized, stratified at 4 uC and germinated on half-strength Murashige and Skoog agar plates containing 1 mM, 3 mM or 10 mM MeJA or 0.1% DMSO (control). Plates were placed vertically in a growth chamber (16 h light/8 h dark light cycle, 100 mE s 21 m 22 light intensity) for 10 days before pictures were taken, and root lengths were measured with ImageJ software (http://rsbweb.nih.gov/ij/). Bacterial infection. Pseudomonas syringae pathovar tomato (Pst) DC3000 infection assays in Arabidopsis plants were performed as described previously 41 . Briefly, 5-week-old Arabidopsis plants were dip-inoculated with Pst DC3000 bacterial RESEARCH LETTER suspension (1 3 10 8 colony-forming units per millilitre, 0.025% Silwet-L77). Bacterial growth was determined 3 days after inoculation. HDX mass spectrometry. HDX of MYC3(5-242) in 20 mM Tris pH 8.0, 200 mM ammonium acetate, 1 mM EDTA and 7% glycerol was performed at 4 uC using an automated system described previously 42 . Briefly, protein was incubated in a D 2 O buffer for a range of exchange times from 10 s to 1 h before quenching the deuterium exchange reaction with an acidic quench solution (pH 2.4) containing 3 M urea and 1% TFA. All mixing and digestions were performed on a LEAP Technologies Twin HTS PAL liquid handling robot housed inside a temperaturecontrolled fridge. Protein digestion was performed in-line with chromatography using an immobilized pepsin column. Mass spectra were acquired on a Q Exactive hybrid quadrupole-Orbitrap mass spectrometer (ThermoFisher Scientific). Percentage deuterium exchange values for peptide isotopic envelopes at each time point were calculated and processed using Workbench software 43 .
The unit of measurement represented as a single value is the percentage deuterium incorporation, which is determined by initially calculating the intensity weighted average (centroid) of all spectral data within defined m/z limits. The percentage deuterium incorporation is then determined by comparing the result to defined minimum (0%) and maximum (100%) m/z values for each peptide. The minimum and maximum m/z values are determined using experimentally observed undeuterated and fully deuterated controls.
The data representing each peptide are reduced to single values in the following manner. For each sample, the three individual time-point replicates of the percentage deuterium incorporation (done in triplicate) at each time point are averaged. The mean of these values is then presented as a single value, representing the overall change in deuterium incorporation for the sample. The first number in brackets is the representation of the propagation of error for the sample, which is determined by a root mean squared approach using the standard deviations from each individual time point. The second number in brackets is the charge state of the detected peptide.
Extended Data Fig. 4a shows cumulative peptides fragments that were detected in tandem mass spectrometry. Shorter fragments (four to ten residues) provide higher resolution information than longer peptides. Therefore, they supersede longer fragments (more than ten residues) and were used to manually overlay onto the atomic structure as in the case of Fig. 2b . No subtraction was used. The peptide set used for structural overlay contained the shortest fragments from the complete data set (all peptides). Data analysis, statistics and experimental repeats. The specific statistical method used, the sample size and the results of statistical analyses are described in the relevant figure legends. No statistical methods were used to predetermine sample size. Sample size was determined on the basis of experimental trials and in consideration of previous publications on similar experiments to allow for confident statistical analyses. The experiments were not randomized. The investigators were not blinded to allocation during experiments and outcome assessment. All reported results were reproduced in at least three independent experiments.
